Fig. 1: Effects of tirzepatide on pressure overload and volume expansion.

a, Least-squares mean changes from baseline in systolic BP (SBP) plotted as a function of duration of treatment in participants randomized to tirzepatide (red circles) or placebo (black squares). b, The estimated mean treatment difference in the change in BV versus baseline with tirzepatide (TZP) compared with placebo plotted as a function of duration of treatment. The error bars represent s.e.m. for both panels; two-sided P < 0.001 for each time point comparison for a and b based upon comparing the least-squares means calculated from a mixed-model repeated-measures model incorporating baseline value, sex, history of HF decompensation within 12 months, diabetes status, baseline BMI group (<35, ≥35 kg m⁻²), treatment assignment, time, and treatment × time interaction. No correction was made for multiple hypothesis testing.